A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007752/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy
results in a clinically significant improvement in progression free survival (PFS) as
compared to treatment with ofatumumab in patients with relapsed or refractory Chronic
Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
提供机构：
Vivli
创建时间：
2022-02-17
